Ensoma Stock

Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.

Sign up today and learn more about Ensoma Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Ensoma Stock

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

Funding History

February 2021$70.0M
January 2023$85.0M
May 2023$50.0M

Management

Board of Directors

Kouki Harasaki

Chief Operating Officer

Min Wang

Board Member

Kush Parmar

Chairman of the Board

Paula Soteropoulos

Board Member

Albert Seymour

CEO

Emile F. Nuwaysir

Board of Directors

Mark Chin

Co-Founder & Scientific Advisor

Andre Lieber

Board Member

Stephen Knight

Board of Directors

Paula Soteropoulos

Board of Directors

Emile F. Nuwaysir

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo